{
  "id": 485095,
  "title": "AbCellera details 'striking' Phase 2 data for vasomotor symptoms treatment",
  "url": "https://urgent.news/2026/08/10/abcellera-details-striking-phase-2-data-for-vasomotor-symptoms",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-10T15:33:49.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/abcellera-details-striking-phase-2-data-for-vasomotor-symptoms-treatment/"
  },
  "original_language": "en",
  "account": null,
  "summary": "AbCellera’s share price {$ABCL} climbed about 31% by mid-morning Monday after the biotech shared positive data from a mid-stage hot flashes trial that surpassed Wall Street's expectations. The biotech’s NK3R (neurokinin 3 receptor)-targeting antibody, known ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Financial Post",
        "title": "AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile",
        "url": "https://urgent.news/2026/08/10/abcellera-announces-positive-top-line-phase-2-clinical-trial-results",
        "published": "2026-08-10T11:06:48.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}